Autolus Therapeutics plc financial data

Symbol
AUTL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
The Mediaworks, 191 Wood Lane, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Autolus Therapeutics Ltd (to 6/8/2018)
Latest financial report
10-K - Q4 2024 - Mar 20, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.49K % +81.6%
Debt-to-equity 67.1 % -41.5%
Return On Equity -43.8 % +58.6%
Return On Assets -26.2 % +46.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 266M shares +0.08%
Entity Public Float 614M USD +120%
Weighted Average Number of Shares Outstanding, Basic 255M shares +46.7%
Weighted Average Number of Shares Outstanding, Diluted 255M shares +46.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 138M USD +6.1%
General and Administrative Expense 83.1M USD +116%
Operating Income (Loss) -241M USD -34.3%
Nonoperating Income (Expense) 22.3M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -219M USD -5.15%
Income Tax Expense (Benefit) 1.53M USD
Net Income (Loss) Attributable to Parent -221M USD -5.89%
Earnings Per Share, Basic -0.86 USD/shares +28.3%
Earnings Per Share, Diluted -0.86 USD/shares +28.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 227M USD -5.09%
Accounts Receivable, after Allowance for Credit Loss, Current 15K USD -86.2%
Inventory, Net 4.14M USD
Other Assets, Current 1.57M USD
Assets, Current 661M USD +140%
Deferred Income Tax Assets, Net 3.24M USD +5.75%
Property, Plant and Equipment, Net 49.6M USD +42.1%
Operating Lease, Right-of-Use Asset 55.5M USD -8.71%
Assets 783M USD +109%
Accounts Payable, Current 1.97M USD +1812%
Employee-related Liabilities, Current 19.7M USD +33.4%
Accrued Liabilities, Current 52.3M USD +32.1%
Contract with Customer, Liability, Current 3.5M USD
Liabilities, Current 60.7M USD +35.8%
Contract with Customer, Liability, Noncurrent 245M USD +43.1%
Operating Lease, Liability, Noncurrent 49.6M USD +3.58%
Other Liabilities, Noncurrent 426K USD +19.3%
Liabilities 355M USD +34.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -29.2M USD -0.63%
Retained Earnings (Accumulated Deficit) -1.1B USD -25.1%
Stockholders' Equity Attributable to Parent 427M USD +283%
Liabilities and Equity 783M USD +109%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -40.5M USD +4.49%
Net Cash Provided by (Used in) Financing Activities 561M USD
Net Cash Provided by (Used in) Investing Activities -533K USD +85.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 519M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 229M USD -4.8%
Deferred Tax Assets, Valuation Allowance 157M USD +27.7%
Deferred Tax Assets, Gross 160M USD +27.2%
Operating Lease, Liability 52.6M USD -0.64%
Depreciation 7.6M USD +15.2%
Payments to Acquire Property, Plant, and Equipment 533K USD -85.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -221M USD -11.3%
Lessee, Operating Lease, Liability, to be Paid 105M USD +15.9%
Operating Lease, Liability, Current 3M USD -40.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.05M USD +16.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.85M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +13.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 52.6M USD +38.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.35M USD +25.3%
Deferred Tax Assets, Operating Loss Carryforwards 136M USD +30.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.64M USD +17.1%
Operating Lease, Payments 1.73M USD +33.1%
Additional Paid in Capital 1.56B USD +52.7%
Depreciation, Depletion and Amortization 1.81M USD -4.9%
Share-based Payment Arrangement, Expense 15.5M USD +38.1%
Interest Expense 9.29M USD -79.4%